Table 1 Baseline characteristics of complete and incomplete response group in patients with nasopharyngeal cancer
n | Study group | |||
|---|---|---|---|---|
Incomplete response group (%) | Complete response group (%) | p | ||
Age (mean ± St.D.) | 45.9 ± 14.5 | 48.3 ± 11.9 | 0.38 | |
Gender (n) | Female | 31 (33.7) | 36 (39.2) | 0.52 |
Male | 7 (7.6) | 18 (19.5) | ||
T stage (n) | T1 | 16 (17.4) | 20 (21.7) | 0.33 |
T2 | 8 (8.7) | 24 (26.1) | ||
T3/T4 | 14 (15.2) | 10 (10.9) | ||
N stage (n) | N0 | 5 (5.4) | 7 (7.6) | 0.91 |
N1 | 10 (10.9) | 12 (13) | ||
N2 | 20 (21.7) | 32 (34.8) | ||
N3 | 3 (3.3) | 3 (3.3) | ||
Clinical stage (n) | Stage 1 | 3 (3.3) | 2 (2.2) | 0.74 |
Stage 2 | 6 (6.5) | 11 (12) | ||
Stage 3 | 25 (27.2) | 37 (40.2) | ||
Stage 4a | 4 (4.3) | 4 (4.3) | ||
Histological type (n) | Keratinizing SCC | 13 (14.1) | 8 (8.7) | 0.06 |
Non- Keratinizing differentiated carcinoma | 13 (14.1) | 19 (20.7) | ||
Non- Keratinizing differentiated carcinoma | 12 (13) | 27 (29.3) | ||
Smoking (n) | No | 22 (23.9) | 30 (32.6) | 0.82 |
Yes | 16 (17.4) | 24 (26.1) | ||
ECOG-PS (n) | 0 | 2 (2.2) | 5 (5.4) | 0.47 |
1 | 36 (39.1) | 49 (53.3) | ||
Induction chemotherapy (n) | No | 22 (23.9) | 38 (41.3) | 0.21 |
Yes | 16 (17.4) | 16 (17.4) | ||
Definitive RT/CRT (n) | RT | 2 (2.2) | 2 (2.2) | 0.71 |
CRT | 36 (39.1) | 52 (56.5) | ||
Adjuvant chemotherapy (n) | No | 26 (28.3) | 34 (37) | 0.58 |
Yes | 12 (13) | 20 (21.7) | ||
Cisplatin dose with RT (n) | 40 mg/m2 weekly | 21 (24.7) | 25 (29.4) | 0.16 |
100 mg/m2 once every 3 weeks | 12 (14.1) | 27 (31.8) | ||
Recurrence/metastasis (n) | Yes | 15 (16.3) | 9 (9.8) | 0.014 |
No | 23 (25) | 45 (48.9) | ||